Skip to Content

Prescient Therapeutics Ltd PSTTF Stock Quote

| Rating as of


Morningstar‘s Stock Analysis PSTTF

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics PSTTF

Company Profile PSTTF

Business Description

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Level 4, 100 Albert Road, South Melbourne
Melbourne, VIC, 3205, Australia
T +61 396927222
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Jun 30, 2023
Employees 1